FactSet Survey: 9 Analysts Lower Roivant Sciences 2027 EPS Median to -$1.22

Summary

According to a FactSet survey, 9 analysts have lowered Roivant Sciences’ (ROIV) median 2027 EPS estimate to -$1.22 from -$1.20, with the target price adjusted to $39.50 AnueSec. This follows a brief upward revision to -$1.20 recorded just last week AnueSec.

Impact Analysis

So basically, we’re seeing analysts hair-splitting over a two-cent revision for a year that’s still three years away AnueSec+ 2. The interesting part isn’t the -$1.22 EPS; it’s the volatility in the consensus. Just last week, the sentiment swung the other way AnueSec, suggesting the Street is struggling to pin down a valuation for Roivant’s ‘Vant’ model.

Market’s missing that for a biotech aggregator, 2027 earnings are largely speculative and highly dependent on lumpy milestone payments or spin-off events. I’d read this as noise rather than a fundamental decay in the thesis. The real signal is the target price hovering near $40 AnueSec—analysts are clearly hitting a valuation ceiling. While the EPS tweak is negligible, it reflects a defensive posture. I’m not trading on a $0.02 adjustment, but I’m watching for any real pipeline delays that would actually justify moving that $39.50 target lower. For now, it’s a ‘wait and see’ on execution, not a spreadsheet crisis.